Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120122 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL1771016 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL20853080 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL27771224 | 0.98 | FAAH (0.40) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL486953 | 0.95 | ALDH1A1 (0.38) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL486954 | 0.95 | ALDH1A1 (0.38) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL486952 | 0.95 | ALDH1A1 (0.38) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL9278970 | 0.94 | FAAH (0.39) | ALDH1A1TSHRFAAHTRPV1MGLL | |
| SCHEMBL2421570 | 0.93 | FAAH (0.34) | ALDH1A1TSHRFAAHMGLL | |
| SCHEMBL2421576 | 0.93 | FAAH (0.34) | ALDH1A1TSHRFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | claimed |
| EP-4433045-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | KINDRA CORPORATION (US) | 2024-09-25 | — | — | EP | claimed |
| CN-118510501-A | Formulations and methods for treating climacteric symptoms | 金卓拉公司 | 2024-08-16 | — | — | CN | claimed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | claimed |
| EP-2854750-B1 | TRPA1 ANTAGONISTS FOR REDUCING NEGATIVE SENSATIONS CAUSED BY HYDROGEN PEROXIDE | PROCTER & GAMBLE (US) | 2019-10-02 | — | — | EP | claimed |
| CN-104472481-A | Bed bug control and repellency | BEDOUKIAN RES INC | 2015-04-01 | — | — | CN | claimed |
| EP-2424355-B1 | BED BUG CONTROL AND REPELLENCY | BEDOUKIAN RES INC (US) | 2015-03-18 | — | — | EP | claimed |
| CN-102413686-B | Control and repellency of bed bugs | BEDOUKIAN RES INC | 2014-12-10 | — | — | CN | claimed |
| US-8551510-B2 | Bed bug control and repellency | BEDOUKIAN RESEARCH, INC. (US) | 2013-10-08 | — | — | US | claimed |
| CN-102413686-A | Control and repellency of bed bugs | BEDOUKIAN RES INC | 2012-04-11 | — | — | CN | claimed |
| US-20120046359-A1 | Bed bug control and repellency | BEDOUKIAN ROBERT H (US) | 2012-02-23 | — | — | US | claimed |
| US-20260096991-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | XAMPLA LTD (GB) | 2026-04-09 | — | — | US | disclosed |
| EP-4489592-B1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250255827-A1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-08-14 | — | — | US | disclosed |
| EP-4593639-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | Xampla Limited (GB) | 2025-08-06 | — | — | EP | disclosed |
| US-20100152083-A1 | Perfume Systems | PROCTER & GAMBLE COMPANY, THE | 2010-06-17 | — | — | US | disclosed |
| WO-2009027957-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-1765139-A1 | ROLLER FOR PROVIDING BENEFITS TO FABRIC | The Procter and Gamble Company (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006010087-A1 | ROLLER FOR PROVIDING BENEFITS TO FABRIC | THE PROCTER & GAMBLE COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060005333-A1 | Roller for providing benefits to fabric | PROCTER & GAMBLE COMPANY, THE | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096991-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | PCTP, CLK4, MTCL3 | ALDH1A1 4813/4885TSHR 2408/4885FAAH 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.